The knowledge used to guide treatment is built from research, and research is built from the people who are invited, able, and willing to take part. That makes a quiet but consequential question worth asking: whose bodies and experiences is a body of health evidence built from, what can it tell us, and for whom?

Representation shapes what evidence can tell us

Representation is not only a question of fairness or enrollment numbers. It affects the reach, reliability, and applicability of evidence. When a treatment is studied mainly in one population, its safety and effectiveness in others may rest on extrapolation rather than direct evidence. Differences between groups can remain invisible, and people who were not adequately represented may receive care based on evidence that does not describe their circumstances well.

Underrepresentation can arise across many dimensions, including race and ethnicity, sex and gender, age, disability, socioeconomic position, geography, language, and the presence of multiple conditions. These categories are not interchangeable, and no study can represent every population. The point is to make the scope of the evidence visible rather than presenting it as universal when it is not.

Recent U.S. oversight has found continuing gaps between the expectation that clinical trials include underrepresented populations and what some trials actually plan or achieve. Work on broadening eligibility criteria has also shown that changes to study design can materially widen access to trials, including for groups that have historically been less likely to qualify. Representation is shaped upstream, through eligibility rules, recruitment locations, compensation, transport, language access, follow-up requirements, and the questions researchers choose to ask.

History, trust, and the conditions for participation

Who takes part is not simply a matter of individual willingness. Participation requires time, travel, information, safety, trust, and a reasonable belief that the research will be conducted respectfully and produce value. These conditions are distributed unevenly.

Trust also has a history. In the United States, well-documented research abuses, including the Tuskegee syphilis study, shaped justified wariness toward medical institutions. Other communities around the world have their own histories of exploitation, exclusion, extractive research, or promised benefits that did not reach the people who participated. Telling underrepresented groups to trust research without changing institutional conduct mistakes a relationship problem for a persuasion problem.

More credible participation requires institutions to earn trust through transparent communication, community partnership, accessible design, fair treatment, meaningful consent, and accountability for what happens after a study ends. It also requires asking whether participation is practically possible for people whose lives, work, health, or resources do not fit the assumptions built into a research protocol.

From representation to research quality

Representation should not be reduced to a target that can be met at the end of recruitment. It is a design question from the beginning: whose experiences are relevant, what barriers may exclude them, who helps shape the study, what outcomes are measured, and how findings will be communicated and used.

Broader participation is not a guarantee of better evidence by itself. Studies still need sound methods, appropriate analysis, respectful governance, and transparent reporting. But without attention to who is represented and under what conditions, the evidence base can remain narrower than the population it is used to serve.

This is a health-psychology question because participation is shaped by perception, trust, identity, relationships, institutions, and the meaning people assign to research. It is also a scientific and ethical question. Better evidence requires both methodological quality and attention to whose lives the evidence is meant to describe.

Questions to leave with

• When you read a health finding, who was it built from, and who was left out?

• What can the evidence actually tell us, and about whom?

• Where is the evidence base thin? Were the practical conditions of participation realistic?

• Did the institution asking for participation earn the trust it required?

• And what would make broader participation genuinely possible, rather than merely encouraged?

For deeper reading